Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective
Journal of Medical Economics | May 12, 2025 | Volume: 28 | Issue: 1 | Pages: 709-718
10.1080/13696998.2025.2503661
| PMID 40351121